Business Wire

REPLY: Reply Crypto Investment Challenge Kicks Off, Organised by Reply and Young Platform, to Promote Conscious Investment in Digital Assets

7.4.2023 10:00:00 EEST | Business Wire | Press release

Share

The fourth edition of the Reply Investment Challenge kicks off, focusing for the first time on Digital Assets, Crypto, and Blockchain. Aimed at students and young professionals, the international online competition in 2022 counted 13,750 entries from 95 countries around the world and a total volume of 36,000 trades executed.

The objective of the Challenge, which will take place from Monday 8 May to Friday 19 May 2023, will be to bring participants closer to the world of digital assets and Blockchain, promoting an informed use of these financial instruments and paying particular attention to the issue of portfolio diversification. Players will also be able to choose between two different interfaces: a more simple and more intuitive one and a more complete and detailed one, respectively Young Platform and Young Platform Pro.

Participants will be able to practice until 5 May in a protected environment, expanding their skills on digital financial instruments, and in particular on cryptocurrencies, as well as on the Blockchain as an enabling technology. The virtual capital of EUR 1 million that each player will have at their disposal will be made available at the time of registration, and all transactions will be conducted at current market values. In the month leading up to the competition, moreover, on the Challenge platform, all participants will be able to access exclusive e-learning content, created by Reply, Young Platform and POLIMI Graduate School of Management.

At the start of the competition, on 8 May, the participants' wallets will be re-credited with the virtual sum of € 1,000,000 to be invested in real-time and the challenge can begin. Challengers will be ranked and evaluated based on their investment choices and the strategy implemented in response to the suggestions published by Reply. Only the top three, i.e. those who, more than the others, have succeeded in maximising their portfolio's return through diversification, will win the competition.

This year Reply has chosen Young Platform, Italy's largest regulated cryptocurrency platform, as its partner. Young Platform is a Turin-based scale-up founded in 2018 to make the cryptocurrency market accessible to all. The platform acts as a point of reference for those who want to use digital assets in a simple, transparent, and effective way, even without having specific expertise in the sector. It stands out for its focus on security, training, and the privacy of its users, guaranteeing the use of cutting-edge technologies to protect data and transactions.

Reply, thanks to its expertise in Blockchain and distributed technology, supports various financial institutions, as well as major players in sectors such as healthcare, energy & utilities, fashion & luxury, and others, in the adoption of digital assets, thus positioning itself as a reference player in the Crypto and Blockchain field.

The POLIMI Graduate School of Management, with its participation in the Reply Crypto Investment Challenge, confirms its commitment to educating and training risk-conscious financial operators in investments.

The Reply Crypto Investment Challenge is part of Reply's Challenges program, which, together with the Masters in Digital Finance at POLIMI Graduate School of Management and in AI & Cloud at the Politecnico di Torino and the Reply Code For Kids program, are just some of the examples that bear witness to Reply's commitment to the development of innovative training models, capable of involving the new generations. Today Reply's Challenges have a community of over 140,000 players.

Registration for the Reply Crypto Investment Challenge is open until 5 May 2023. All information is available at: challenges.reply.com.

Reply

Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com

Young Platform

Young Platform is a Turin-based scale-up founded in 2018 to make the cryptocurrency market accessible to everyone. The platform acts as a reference point for those who want to use cryptocurrencies in a simple, transparent, and effective way, even without having specific expertise in the field. Young Platform offers a wide range of tools and services, including the possibility to buy and sell cryptocurrencies and earn tokens using learning games, and advanced trading tools. The platform stands out for its focus on the security and privacy of its users, guaranteeing the use of state-of-the-art technology to protect data and transactions, relying exclusively on Italian banks. Young Platform considers compliance a priority aspect of technological innovation. For this reason, it has always been committed to developing cutting-edge solutions to manage the risk of financial crime and to structuring specialised blockchain intelligence aimed at combating money laundering and the financing of terrorism, working with regulators and law enforcement agencies. Young Platform is the first company officially registered with the Organismo Agenti e Mediatori (OAM) in Italy and was recently certified as a digital asset services operator (PSAN) by the French Financial Markets Authority.

POLIMI Graduate School of Management

At POLIMI Graduate School of Management, we inspire tomorrow's business leaders and the companies they work in, knowing that they can play a crucial role in creating a better future for everyone. Indeed, we believe that education is of fundamental importance, as it provides tomorrow's leaders with the skills and experience they will need to tackle the most important challenges facing our society. Our School, founded over 40 years ago in Milan as MIP Politecnico di Milano, is today a non-profit joint-stock consortium, made up of the University and a group of leading Italian and international companies. We offer more than 40 master's degrees, including MBAs and Executive MBAs, a catalog of over 200 open programs, and tailor-made training courses for companies. We are innovative and always want to be more so. That is why today our Online MBA is recognised as one of the best in the world and why the digital component is present in all our training offerings. As part of the School of Management, we are one of the few schools in the world to have achieved 'Triple Crown' accreditation. With more than 15,000 Alumni and 3,000 students each year, we are a large, innovative, and entrepreneurial community of people and partners. For us, relationships are a source of constant enrichment, innovation, and inspiration, both personally and professionally. For us, the issue of sustainability is really important and we strive to build a better, fairer, more inclusive, and conscious future. We do this with projects and initiatives that maximise our positive impact on society. This is why, in 2020, we were the first European business school to receive the B Corp certification. www.gsom.polimi.it

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media contacts:

R eply
Fabio Zappelli
f.zappelli@reply.com
Tel. +390117711594

Aaron Miani
a.miani@reply.com
Tel. +44 2077 306000

Young Platform
Jacqueline Nieder
j.nieder@young.business
Tel. +39 349 3091984

POLIMI Graduate School of Management
Sergio Oliveri
+39 338 5617836
oliveri@mip.polimi.it

L45 Corporate Relations
Alessandro D’Angelo
+39 329 4139226
adangelo@l45.it

Hind Misbah
+39 329 5425659
hind@l45.it

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye